In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Chronic use of topical hypotensive agents induces several side effects caused by preservatives. The purpose of this study was to evaluate the effects of prostaglandin analogs with varying concentrations of benzalkonium chloride (BAC), preservative-free (PF), and alternative preservatives on mouse corneal tissue. Methods: Thirty-five, 8- to 10-week-old female C57BL/6 mice (five mice for each group) were used for this study. To the control group, we applied normal saline, and to each drug-treated group we applied 0.02% BAC, bimatoprost 0.01% (with BAC 0.02%), latanoprost 0.005% (with BAC 0.02%), travoprost 0.004% (with 0.001% polyquad) or tafluprost 0.0015% with/without 0.001% BAC, once a day (9 p.m.) for 4 weeks. Corneal fluorescein staining was evaluated in all groups. After harvest, the corneal tissues were embedded in paraffin and then Hematoxylin-Eosin stain was performed for histopathological examination. Immunofluorescence staining was done against TNF-α, IL-6, HLA DR, pJNK, and pAkt. Results: In corneal fluorescein staining, severe punctate epithelial keratitis was seen in the groups of 0.02% BAC, 0.02% BAC containing bimatoprost 0.01% and latanoprost 0.005%. The surface desquamation, irregular surface, loss of cell borders, anisocytosis and stromal shrinkage were observed in the groups of BACcontaining eye drops. Moreover, the groups treated with BAC-containing eye drops have high inflammatory markers, significantly decreased cell viability-related signal, pAkt, and higher apoptosis-inducing signal, pJNK, than the control group. On the other hand, travoprost 0.004% and PF tafluprost 0.0015% have less cellular morphologic changes, lower inflammation, and higher cellular viability than BAC-containing formulations. Conclusions: Corneal damage, increased inflammation and apoptosis and low cell viability were observed in BAC-containing groups. PF or alternatively preserved glaucoma medications seem to be a reasonable and viable alternative to those preserved with BAC.
Abstract
Purpose: Chronic use of topical hypotensive agents induces several side effects caused by preservatives. The purpose of this study was to evaluate the effects of prostaglandin analogs with varying concentrations of benzalkonium chloride (BAC), preservative-free (PF), and alternative preservatives on mouse corneal tissue. Methods: Thirty-five, 8- to 10-week-old female C57BL/6 mice (five mice for each group) were used for this study. To the control group, we applied normal saline, and to each drug-treated group we applied 0.02% BAC, bimatoprost 0.01% (with BAC 0.02%), latanoprost 0.005% (with BAC 0.02%), travoprost 0.004% (with 0.001% polyquad) or tafluprost 0.0015% with/without 0.001% BAC, once a day (9 p.m.) for 4 weeks. Corneal fluorescein staining was evaluated in all groups. After harvest, the corneal tissues were embedded in paraffin and then Hematoxylin-Eosin stain was performed for histopathological examination. Immunofluorescence staining was done against TNF-α, IL-6, HLA DR, pJNK, and pAkt. Results: In corneal fluorescein staining, severe punctate epithelial keratitis was seen in the groups of 0.02% BAC, 0.02% BAC containing bimatoprost 0.01% and latanoprost 0.005%. The surface desquamation, irregular surface, loss of cell borders, anisocytosis and stromal shrinkage were observed in the groups of BACcontaining eye drops. Moreover, the groups treated with BAC-containing eye drops have high inflammatory markers, significantly decreased cell viability-related signal, pAkt, and higher apoptosis-inducing signal, pJNK, than the control group. On the other hand, travoprost 0.004% and PF tafluprost 0.0015% have less cellular morphologic changes, lower inflammation, and higher cellular viability than BAC-containing formulations. Conclusions: Corneal damage, increased inflammation and apoptosis and low cell viability were observed in BAC-containing groups. PF or alternatively preserved glaucoma medications seem to be a reasonable and viable alternative to those preserved with BAC.
참고문헌 (29)
- Goldberg I, "Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension", J Glaucoma, 10, pp.414~422 (2001)
- Alm A, "Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol", Scandinavian Latanoprost Study Group. Ophthalmology, 102, pp.1743~1752 (1995)
- Sherwood M, "Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure", Surv Ophthalmol, 45(4), pp.361~368 (2001)
- Broadway DC, "Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery", Arch Ophthalmol, 112, pp.1446~1454 (1994)
- Baudouin C, "Allergic reaction to topical eyedrops", Curr Opin Allergy Clin Immunol, 5, pp.459~463 (2005)
- Noecker RJ, "Corneal and conjunctival changes caused by commonly used glaucoma medications", Cornea, 23, pp.490~496 (2004)
- Jaenen N, "Ocular symptoms and signs with preserved and preservative-free glaucoma medications", Eur J Ophthalmol, 17, pp.341~349 (2007)
- Brasnu E, "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", Curr Eye Res, 33, pp.303~312 (2008)
- Baudouin C, "The ocular surface in glaucoma", Cornea, 28, pp.14~19 (2009)
- Baudouin C, "Preservatives in eyedrops:the good, the bad and the ugly", Prog Retin Eye Res, 29, pp.312~334 (2010)
- Baudouin C, "Ocular surface inf lammatory changes induced by topical antiglaucoma drugs: human and animal studies", Ophthalmology, 106, pp.556~563 (1999)
- Pisella PJ, "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", Br J Ophthalmol, 86, pp.418~423 (2002)
- Noecker R, "Effects of common ophthalmic preservatives on ocular health", Adv Ther, 18, pp.205~215 (2001)
- De Saint Jean M, "Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells", Invest Ophthalmol Vis Sci, 40, pp.619~630 (1999)
- Baudouin C, "In vitro studies of antiglaucomatous prostaglandin analogues:travoprost with and without benzalkonium chloride and preserved latanoprost", Invest Ophthalmol Vis Sci, 48, pp.4123~4128 (2007)
- Guenoun JM, "In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells", Invest Ophthalmol Vis Sci, 46, pp.2444~2450 (2005)
- 이정규, "항녹내장 약제가 배양된 사람 결막상피세포의 미치는 영향", 대한안과학회지, 47(11), pp.1811~1818 (2006), 대한안과학회
- Liang H, "Conjunctival and corneal reactions in rabbits following shortand repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride", Br J Ophthalmol, 92, pp.1275~1282 (2008)
- Tripathi BJ, "Cytotoxicity of ophthalmic preservatives on human corneal epithelium", Lens Eye Toxic Res, 9, pp.361~375 (1992)
- Asada H, "Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy", Yakugaku Zasshi, 130, pp.867~871 (2010)
- Nakagawa S, "Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets", Invest Ophthalmol Vis Sci, 53, pp.5154~5160 (2012)
- Liang H, "Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study", PLoS One, 7, pp.33913~ (2012)
- Liang H, "Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions", Ophthalmic Res, 48, pp.89~101 (2012)
- 김은주, "In Vitro Effects of Preservative-free and Preserved Prostaglandin Analogs on Primary Cultured Human Conjunctival Fibroblast Cells", Korean Journal of Ophthalmology, 27(6), pp.446~453 (2013), 대한안과학회
- Pauly A, "In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation", Invest Ophthalmol Vis Sci, 53, pp.8172~8180 (2012)
- Liang H, "Polyquad-preserved travoprost", timolol, benzalkonium chloride (BAK)-preserved travoprost, timolol in fixed combinations: a rabbit ocular surface study, pp.Adv Ther, 2011[DOI]
- Lu L, "UV-induced signaling pathways associated with corneal epithelial cell apoptosis", Invest Ophthalmol Vis Sci, 44, pp.5102~5109 (2003)
- Chen F, "JNK-induced apoptosis, compensatory growth, and cancer stem cells", Cancer Res, 72, pp.379~386 (2012)
- Niwano Y, "Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog", Ophthalmol Eye Dis, 6, pp.5~12 (2014)